BNT162b2 mRNA新冠疫苗在造血干细胞移植受者中的免疫原性与安全性
该前瞻性研究纳入152例移植后至少6个月且无活动性急性GVHD的异基因HSCT受者,接种第二剂BNT162b2后2-4周检测RBD抗体和中和抗体,并与272名免疫健全医护人员对照。结论认为该疫苗在HSCT受者中安全有效,尤其对无免疫抑制治疗者。
要点
- 无慢性GVHD且未接受免疫抑制治疗者中和抗体水平显著更高。
核心结论
- BNT162b2 mRNA疫苗在HSCT受者中安全有效,尤其对无免疫抑制治疗者。
- 相当一部分HSCT受者产生了保护性中和抗体。
研究设计与样本
- 前瞻性随访152例异基因HSCT受者,移植后至少6个月且无活动性急性GVHD。
- 第二剂接种后2-4周采血检测RBD抗体和中和抗体。
- 272名免疫健全医护人员作为对照组。
主要发现
- 多因素logistic回归显示,接种时无慢性GVHD且未接受免疫抑制治疗的HSCT受者中和抗体水平显著更高。
- 不良事件轻微,且比健康对照更少见。
临床怎么用
- HSCT受者接种BNT162b2疫苗总体安全,可考虑接种。
- 对无慢性GVHD且未接受免疫抑制治疗者,疫苗免疫应答可能更好。
- HSCT受者接种后抗体水平仍低于健康人群,需关注保护力评估。
局限性
- 原文摘要未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The immunogenicity and safety of Pfizer-BioNTech BNT162b2 mRNA vaccine in allogeneic haematopoietic stem cell transplantation (HSCT) recipients are unknown. We prospectively followed 152 HSCT recipients who were at least six months following transplantation and with no active acute graft-versus-host disease (GVHD). Blood samples were taken 2-4 weeks after the second vaccination and analyzed for receptor-binding domain (RBD) antibodies and neutralizing antibodies (NA). 272 immunocompetent healthcare workers served as controls. At a median of 28 days after the second vaccination, 118 patients (77·6%) developed RBD immunoglobulin G (IgG) with a geometric mean titre (GMT) of 2·61 [95% CI (confidence interval), 2·16-3·16]. In the control group 269/272 (98·9%) developed RBD IgG, with a GMT of 5·98 (95% CI 5·70-6·28), P < 0·0001. The GMT of NA in HSCT recipients and controls was 116·0 (95% CI 76·5-175·9), and 427·9 (95% CI 354·3-516·7) respectively (P < 0001). Multivariate logistic regression analysis revealed that HSCT recipients with no chronic GVHD and no immunosuppressive therapy at the time of vaccination had significantly higher levels of NA following the second vaccination. Adverse events were minimal and were less common than in healthy controls. In conclusion; the BNT162b2 mRNA vaccination is safe and effective in HSCT recipients, especially those who are immunosuppression-free. A significant fraction developed protecting NA.
引用
- Shem-Tov N, Yerushalmi R, Danylesko I, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. Br J Haematol. 2021. PMID: 34713441. doi:10.1111/bjh.17918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。